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ORIGINAL INVESTIGATION
Cumulative burden of metabolic syndrome 
and its components on the risk of atrial 
fibrillation: a nationwide population-based 
study
Hyo‑Jeong Ahn1†, Kyung‑Do Han2†, Eue‑Keun Choi1,3* , Jin‑Hyung Jung4, Soonil Kwon1, So‑Ryoung Lee1, 
Seil Oh1,3 and Gregory Y. H. Lip3,5,6
Abstract 
Background: The metabolic syndrome (MetS) and its components are associated with the development of atrial 
fibrillation (AF). However, the impact of time‑burden of MetS on the risk of AF is unknown. We investigated the effect 
of the cumulative longitudinal burden of MetS on the development of AF.
Methods: We included 2 885 189 individuals without AF who underwent four annual health examinations during 
2009–2013 from the database of the Korean national health insurance service. Metabolic burdens were evaluated 
in the following three ways: (1) cumulative number of MetS diagnosed at each health examination (0–4 times); (2) 
cumulative number of each MetS component diagnosed at each health examination (0–4 times per MetS compo‑
nent); and (3) cumulative number of total MetS components diagnosed at each health examination (0 to a maximum 
of 20). The risk of AF according to the metabolic burden was estimated using Cox proportional‑hazards models.
Results: Of all individuals, 62.4%, 14.8%, 8.7%, 6.5%, and 7.6% met the MetS diagnostic criteria 0, 1, 2, 3, and 4 times, 
respectively. During a mean follow‑up of 5.3 years, the risk of AF showed a positive association with the cumulative 
number of MetS diagnosed over four health examinations: adjusted hazard ratios (HRs) with 95% confidence inter‑
vals (CIs) of 1, 2, 3, and 4 times compared to 0 times were 1.18 (1.13–1.24), 1.31 (1.25–1.39), 1.46 (1.38–1.55), and 1.72 
(1.63–1.82), respectively; P for trend < 0.001. All five components of MetS, when diagnosed repeatedly, were indepen‑
dently associated with an increased risk of AF: adjusted HR (95% CI) from 1.22 (1.15–1.29) for impaired fasting glucose 
to 1.96 (1.87–2.07) for elevated blood pressure. As metabolic components were accumulated from 0 to 20 counts, 
the risk of AF also gradually increased up to 3.1‑fold (adjusted HR 3.11, 95% CI 2.52–3.83 in those with 20 cumulative 
components of MetS), however, recovery from MetS was linked to a decreased risk of AF.
Conclusions: Given the positive correlations between the cumulative metabolic burdens and the risk of incident AF, 
maximal effort to detect and correct metabolic derangements even before MetS development might be important to 
prevent AF and related cardiovascular diseases.
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Background
Atrial fibrillation (AF) is the most common sustained 
cardiac arrhythmia associated with an increased risk of 
stroke, heart failure, myocardial infarction (MI), demen-
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2%-4%, and the lifetime AF risk was recently estimated as 
1 in 3 individuals of European ancestry at an index age 
of 55 years [4, 5]. As the incidence of AF is expected to 
increase, management of AF has been emphasized as 
integrating stroke prevention, symptom control, risk fac-
tors management, and lifestyle modification [6, 7].
Metabolic syndrome (MetS) is a cluster of metabolic 
disorders including glucose intolerance, low level of high-
density lipoprotein cholesterol (HDL-C), high level of 
triglyceride (TG), obesity, and hypertension [8, 9]. MetS, 
frequently combined with other atherosclerotic risk fac-
tors, has become a pandemic that increases the risk of 
cardiovascular morbidity and mortality [8, 10].
As both AF and MetS lead to significant cardiovascu-
lar diseases, imposing an enormous healthcare burden, 
many studies have attempted to reveal the relationship 
between MetS and AF development; MetS and its com-
ponents are known to be associated with AF develop-
ment [11, 12]. Elevated levels of inflammation, oxidative 
stress, and mechanical stimuli to the atrium have been 
proposed as the underlying pathophysiology of AF devel-
opment in MetS [10, 13, 14]. Also, insulin resistance has 
been identified as one of the common physiologic mani-
festations significantly associated with both AF and MetS 
[15–18]. Notably, Type 2 diabetes is a well-known inde-
pendent risk factor of AF, and one of the components 
of  CHA2DS2-VASc-score used to identify high-risk AF 
patients for stroke [19, 20]. However, MetS status and its 
components are variable as they can change over time 
dynamically. A recent study demonstrated the association 
between the exposure duration or extent of metabolic 
disturbances and the increased risk of MI and stroke, 
which are AF-related complications [21]. Nonetheless, to 
what extent the time-burden of MetS affects the risk of 
AF itself has not been evaluated. Therefore, we aimed to 
investigate the effect of the cumulative longitudinal bur-
den of MetS on AF development through a nationwide 
population-based cohort analysis.
Methods
We defined a population-based cohort from the National 
Health Information Database (NHID) incorporating all 
data from the National Health Insurance Service, which 
covers the entire population of the Republic of Korea 
(hereafter, Korea). All insured adults aged 40  years and 
older are recommended to undergo biannual general 
health screening without cost [22]. Not only the regular 
health examination records, including laboratory results, 
anthropometric measurements, and detailed lifestyle 
questionnaires, but also sociodemographic data, income-
based insurance contributions, prescription records, 
inpatient and outpatient usage, and date of death of all 
insured Koreans are available in the NHID [22, 23]. The 
Institutional Review Board at the Seoul National Univer-
sity Hospital (E-2009–091-1157) authorized this study.
We selected 3 981 515 adults aged ≥ 20  years who 
underwent four serial health examinations between Jan-
uary 1, 2009, and December 31, 2013, from the NHID. 
Individuals with a prior history of AF and missing values 
of health examination data or covariates were excluded 
(Additional file 1: Fig. S1). Finally, 2 885 189 adults were 
included in the analysis.
Evaluation of metabolic syndrome and the influence 
of cumulative metabolic burden
MetS was defined using modified waist circumference 
(WC) criteria of the Korean Society for the Study of Obe-
sity and the guidelines of the National Cholesterol Educa-
tion Program Third Adult Treatment Panel (NCEP-ATP 
III) as the presence of ≥ 3 of the following: increased 
WC [≥ 90  cm in men or ≥ 85  cm in women], elevated 
TG [≥ 150  mg/dL (1.7  mmol/L) or drug treatment for 
elevated TG], low HDL-C [< 40  mg/dL (1  mmol/L) in 
men and < 50  mg/dL (1.3  mmol/L) in women or drug 
treatment for low HDL-C], elevated blood pressure 
[systolic blood pressure ≥ 130  mmHg or diastolic blood 
pressure ≥ 85  mmHg or current use of antihyperten-
sives], and impaired fasting glucose [fasting plasma 
glucose ≥ 100 mg/dL (5.6 mmol/L) or current use of anti-
diabetics] [8, 9, 24].
At each health examination, the presence of MetS itself 
and the number of fulfilled components of MetS were 
calculated. “Metabolic burden” is defined as the following 
three multifaceted ways during four health examinations: 
(1) cumulative number of MetS diagnosed at each health 
examination (0–4 times); (2) cumulative number of each 
MetS component diagnosed at each health examination 
(0–4 times per each MetS component); and (3) cumula-
tive number of total MetS components diagnosed at each 
health examination (0 to a maximum of 20). The overall 
scheme of the study and the three different ways of defin-
ing metabolic burdens are shown in Fig. 1a.
To estimate the influence of temporal trends in meta-
bolic burden on AF incidence, we compared the number 
of metabolic components at the first health examination 
with that at the last examination. The total study popula-
tion was divided into two groups according to the change 
in the number of metabolic components (Fig. 1b).
Group A was defined as the group with a decrease in 
the number of metabolic components, whereas group B 
was defined as that with an increase or maintenance in 
the number of metabolic components at the last health 
examination compared to that in the first examination. 
We stratified groups A and B according to the total 
number of MetS components diagnosed during the 
four health examinations. At each cumulative number 
Page 3 of 13Ahn et al. Cardiovasc Diabetol           (2021) 20:20  
of total MetS components, we matched two groups and 
compared the risk of AF (hazard ratio [HR] with 95% 
confidence interval [CI] of group A was enumerated 
with reference to Group B).
Covariates, follow‑up, and clinical outcomes
Baseline characteristics of the participants were desig-
nated as the data of the last health examination (index 
date), which includes sociodemographic data, income-
based insurance contributions, laboratory results, 
anthropometric measurements, comorbidities (diabetes 
mellitus, hypertension, dyslipidemia, peripheral artery 
disease, chronic obstructive pulmonary disease, myo-
cardial infarction, heart failure, cancer, and chronic 
kidney disease) and answers to detailed lifestyle ques-
tionnaires. We investigated the risk of new-onset AF 
using the International Classification of Diseases, Tenth 
Revision (ICD-10), codes with inpatient and outpatient 
records. Detailed definitions of AF and comorbidities 
are summarized in Additional file 1: Table S1 [22]. The 
follow-up period was the time from the index date to 
the occurrence of AF or December 31, 2018, whichever 
came first.
Statistical analysis
Data are reported as means ± standard deviations for 
continuous variables and number (%) for categorical 
variables. To evaluate significant differences in baseline 
characteristics among groups categorized by the num-
ber of MetS components, one-way analysis of variance 
and chi-square test were used. The incidence rate of AF 
was computed by dividing new-onset AF cases by the 
total follow-up duration and presented as per 1000 per-
son-years (PY). The association between the frequency 
of MetS status and the incidence of AF was estimated 
using Cox proportional hazards regression models. The 
risk of AF according to the number of MetS compared 
to the non-MetS group was expressed as HRs with 95% 
CIs. Model 1 represents an unadjusted risk, and Model 
2 was adjusted for age, sex, smoking status (never 
smoker, ex-smoker, or current smoker), alcohol intake 
(non, mild, or heavy drinker, g/day), regular exercise 
(performing > 30  min of moderate physical activity ≥ 5 
times a week or > 20  min of vigorous physical activ-
ity ≥ 3 times a week), and low-income level (income 
in lower 20% among the entire Korean population of 
subjects supported by the medical aid program) [25]. 
Model 3 was additionally adjusted for WC, systolic 
Fig. 1 a Overall scheme of study and three different ways of defining metabolic burdens. b Evaluation of temporal trends in the metabolic burden 
on the incidence of AF. AF atrial fibrillation, MetS metabolic syndrome, WC waist circumference, HDL-C high‑density lipoprotein cholesterol, BP blood 
pressure, TG triglycerides, Y yes, N no
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blood pressure, fasting glucose, logarithm of TG, and 
HDL-C levels.
To verify the robustness of our results, we performed 
several subgroups and sensitivity analyses with regard to 
the association between the cumulative number of total 
MetS components diagnosed at each health examination 
(0 to a maximum of 20) and the risk of AF. First, we inves-
tigated the association between the cumulative frequency 
of metabolic components and the risk of AF according 
to sex and the presence of obesity to determine poten-
tial effect modifications. We also conducted an analysis 
by excluding participants with AF diagnosed in the first 
2 years of follow-up to minimize the effect of reverse cau-
sality. Data collection and statistical analyses were per-
formed using SAS version 9.4 (SAS Institute, Cary, NC).
Results
The baseline characteristics of 2 885 189 participants 
grouped according to the number of MetS diagnosed 
over four health examinations are summarized in Table 1. 
The mean participant age was 44.5 ± 10.9  years, and 2 
058 645 (71.4%) were men. Individuals were divided into 
five groups: 1 800 268 (62.4%), 428 143 (14.8%), 250 073 
(8.7%), 188 847 (6.5%), and 217 858 (7.6%) who met the 
diagnostic criteria of MetS 0, 1, 2, 3, and 4 times, respec-
tively. Diabetes, hypertension, and dyslipidemia were 
present in 7.1%, 20.7%, and 17.3% of the total population, 
respectively. The prevalence of comorbidities was higher 
as individuals fulfilled more MetS criteria.
Accumulation of metabolic burden and the risk of AF
The follow-up period was 5.3 ± 0.3  years. The incidence 
of AF, according to the number of MetS and the number 
of MetS components during the four health examina-
tions are described in Table 2. The risk of AF showed a 
positive association with the cumulative number of MetS 
diagnosed at each health examination: adjusted HRs 
with 95% CIs of groups meeting the diagnostic criteria of 
MetS 1, 2, 3, and 4 times compared to 0 time were 1.18 
(1.13–1.24), 1.31 (1.25–1.39), 1.46 (1.38–1.55), and 1.72 
(1.63–1.82), P for trend < 0.001. The association is illus-
trated in Fig. 2a.
All five MetS components were independently associ-
ated with the risk of AF. As the number of MetS compo-
nents accumulated, the risk of AF also increased (Table 2 
and Fig.  2b). The effect of each MetS component on 
the risk of AF was different. The adjusted HR (95% CI) 
of each MetS component, when diagnosed four times 
consecutively, was as follows: 1.96 (1.87–2.07) for ele-
vated blood pressure, 1.44 (1.37–1.52) for low HDL-C, 
1.35 (1.27–1.44) for increased WC, 1.27 (1.21–1.34) for 
elevated TG, and 1.22 (1.15–1.29) for impaired fasting 
glucose.
Table  3 and Fig.  2c show the relationship between 
metabolic burden as the cumulative number of all MetS 
components during the four health examinations and the 
risk of AF. As participants had an accumulation of meta-
bolic components from 0 to 20 counts, the risk of AF also 
gradually increased by approximately 3.1-fold compared 
to those without any metabolic components (HR 3.11, 
95% CI 2.52–3.83 in those with 20 components of MetS). 
Kaplan–Meier estimates of the cumulative incidence 
probability of AF are shown in Fig. 3.
Temporal trends of metabolic burden and the risk of AF
We compared the risk of AF according to the temporal 
trends in metabolic burden (Fig. 4 and Additional file 1: 
Table  S2). From 3 to 12 counts of the total cumulative 
metabolic components during the four health examina-
tions, group A (with a decrease in the number of MetS 
components) exhibited a lower risk of AF than group B 
(with an increase or maintenance in the number of MetS 
components). Those with less than 3 or more than 12 
MetS components presented insignificant differences in 
the risk of AF regarding the temporal change in meta-
bolic burden.
Subgroup and sensitivity analysis
Results of subgroup analyses of the association between 
AF risk and the cumulative number of MetS compo-
nents, according to sex and obesity, are shown in Addi-
tional file  1: Table  S3 and Table  S4, respectively. The 
incidence of AF did not show an interaction with sex or 
the presence of obesity (P-for-interaction 0.25 and 0.77, 
respectively).
In sensitivity analysis excluding participants with AF 
diagnosed in the first 2  years of follow-up, the progres-
sive increase in the risk of AF according to the cumula-
tive number of all MetS components was consistent with 
the main results (Additional file 1: Table S5).
Discussion
To the best of our knowledge, this is the first study to 
report the cumulative burden of MetS and its compo-
nents on the risk of AF in a large nationwide population-
based cohort study. We demonstrated several principal 
findings, which are summarized as follows: (1) the cumu-
lative burden of MetS during the four health examina-
tions had a linear correlation with the risk of AF; (2) the 
cumulative burden of each MetS component showed a 
positive association with the risk of AF; (3) among the 
five metabolic components, elevated blood pressure had 
the greatest increase in AF risk; (4) the cumulative num-
ber of total MetS components showed an incremental 
association with the risk of AF; and (5) temporal trends 
in MetS burden had a different effect on the risk of AF.
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Table 1 Baseline characteristics of  the  total study population according to  the  cumulative number of  MetS diagnosed 
at each health examination (0 to 4 times)
Data are presented as means ± SD or No. (Percentages)
Percentages may not total 100 because of rounding
MetS metabolic syndrome, PAD peripheral artery disease, COPD chronic obstructive pulmonary disease, MI myocardial infarction, HF heart failure, CKD chronic kidney 
disease, BMI body mass index, BP blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate
a Alcohol consumption denotes as following
Non-drinker: alcohol consumption 0 g
Mild to moderate drinker: alcohol consumption > 0 g to < 30 g per day
Heavy drinker: alcohol consumption ≥ 30 g per day
b Regular exercise denotes performing > 30 min of moderate-intensity exercise (e.g. brisk pace walking, tennis doubles, or bicycling leisurely) ≥ 5 times a week 
or > 20 min of vigorous-intensity exercise (e.g. running, climbing, fast cycling, or aerobics) ≥ 3 times a week
c Low income denotes income belongs to lower 20% among entire Korean population of subjects supported by the Medical Aid program
Total The number of the presence of metabolic syndrome p
0 1 2 3 4
No. of participants (%) 2,885,189 (100.0) 1,800,268 (62.4) 428,143 (14.8) 250,073 (8.7) 188,847 (6.5) 217,858 (7.6)
Age (years) 44.54 ± 10.85 42.38 ± 10.39 46.30 ± 10.58 47.93 ± 10.66 49.11 ± 10.49 51.07 ± 10.16  < 0.001
Sex
 Male 2,058,645 (71.4) 1,197,934 (66.5) 337,756 (78.9) 200,399 (80.1) 152,483 (80.7) 170,073 (78.1)  < 0.001
 Female 826,544 (28.7) 602,334 (33.5) 90,387 (21.1) 49,674 (19.9) 36,364 (19.3) 47,785 (21.9)
Smoking  < 0.001
 Never smoker 1,369,623 (47.5) 938,078 (52.1) 174,286 (40.7) 97,977 (39.2) 72,215 (38.2) 87,067 (40.0)
 Ex‑smoker 601,896 (20.9) 336,101 (18.7) 100,158 (23.4) 61,532 (24.6) 48,473 (25.7) 55,632 (25.5)
 Current smoker 913,670 (31.7) 526,089 (29.2) 153,699 (35.9) 90,564 (36.2) 68,159 (36.1) 75,159 (34.5)
Alcohol  consumptiona  < 0.001
 Non‑drinker 1,131,332 (39.2) 728,676 (40.5) 156,540 (36.6) 91,741 (36.7) 69,234 (36.7) 85,141 (39.1)
 Mild to moderate drinker 1,511,675 (52.4) 947,766 (52.7) 228,079 (53.3) 130,842 (52.3) 97,706 (51.7) 107,282 (49.2)
 Heavy drinker 242,182 (8.4) 123,826 (6.9) 43,524 (10.2) 27,490 (11.0) 21,907 (11.6) 25,435 (11.7)
 Regular  exerciseb 642,402 (22.3) 390,171 (21.7) 98,815 (23.1) 57,963 (23.2) 43,981 (23.3) 51,472 (23.6)  < 0.001
 Low  incomec 579,366 (20.1) 329,917 (18.3) 89,519 (20.9) 55,953 (22.4) 43,219 (22.9) 60,758 (27.9)  < 0.001
Comorbidities
 Diabetes mellitus 204,495 (7.1) 35,151 (2.0) 28,569 (6.7) 28,964 (11.6) 35,968 (19.1) 75,843 (34.8)  < 0.001
 Hypertension 597,210 (20.7) 173,667 (9.7) 106,689 (24.9) 89,778 (35.9) 88,335 (46.8) 138,741 (63.7)  < 0.001
 Dyslipidemia 499,947 (17.3) 177,145 (9.8) 87,677 (20.5) 68,089 (27.2) 64,119 (34.0) 102,917 (47.2)  < 0.001
 PAD 198,421 (6.9) 76,179 (4.2) 32,740 (7.7) 25,468 (10.2) 24,067 (12.7) 39,967 (18.3)  < 0.001
 COPD 590,393 (20.5) 344,502 (19.1) 89,663 (20.9) 56,012 (22.4) 44,029 (23.3) 56,187 (25.8)  < 0.001
 MI 37,979 (1.3) 15,751 (0.9) 6212 (1.5) 4545 (1.8) 4269 (2.3) 7202 (3.3)  < 0.001
 HF 32,611 (1.13) 12,590 (0.7) 5126 (1.2) 4122 (1.65) 3952 (2.09) 6821 (3.13)  < 0.001
 Cancer 42,378 (1.5) 24,148 (1.3) 6579 (1.5) 4077 (1.6) 3364 (1.8) 4210 (1.9)  < 0.001
 CKD 56,830 (2.0) 23,580 (1.3) 8867 (2.1) 7108 (2.8) 6702 (3.6) 10,573 (4.9)  < 0.001
Laboratory findings
 BMI (kg/m2) 23.84 ± 3.16 22.72 ± 2.66 24.80 ± 2.75 25.68 ± 2.88 26.34 ± 3.00 26.91 ± 3.22  < 0.001
 Waist circumference (cm) 80.79 ± 8.85 77.55 ± 7.76 83.72 ± 7.25 86.15 ± 7.40 87.96 ± 7.58 89.50 ± 8.17  < 0.001
 Systolic BP (mmHg) 121.68 ± 13.55 118.11 ± 12.45 125.18 ± 12.66 127.71 ± 12.91 129.38 ± 13.17 130.65 ± 13.81  < 0.001
 Diastolic BP (mmHg) 76.59 ± 9.48 74.39 ± 8.84 78.80 ± 8.97 80.37 ± 9.19 81.39 ± 9.44 81.94 ± 9.85  < 0.001
 Fasting glucose (mg/dL) 96.7 ± 20.65 91.64 ± 13.28 98.76 ± 19.15 103.09 ± 23.41 108.24 ± 28.56 117.16 ± 36.52  < 0.001
 Total cholesterol (mg/dL) 195.09 ± 35.07 191.10 ± 32.91 200.74 ± 35.66 203.00 ± 37.03 203.23 ± 38.35 200.80 ± 40.45  < 0.001
 HDL cholesterol (mg/dL) 54.78 ± 14.83 58.13 ± 14.4 51.13 ± 13.84 49.00 ± 13.74 47.55 ± 13.41 47.08 ± 13.73  < 0.001
 LDL cholesterol (mg/dL) 113.98 ± 32.14 111.91 ± 30.09 118.58 ± 33.16 118.82 ± 34.72 117.50 ± 35.94 113.46 ± 37.65  < 0.001
 eGFR (ml/min/1.73m2) 92.75 ± 37.86 94.19 ± 38.14 91.57 ± 37.51 90.37 ± 37.02 89.73 ± 38.14 88.56 ± 36.24  < 0.001
 Triglyceride (mg/dL) 135.98 ± 92.48 106.77 ± 64.50 160.86 ± 94.11 184.62 ± 106.67 201.99 ± 114.90 215.47 ± 126.08  < 0.001
Medication
 Statin 245,676 (8.5) 56,971 (3.2) 39,209 (9.2) 36,314 (14.5) 38,637 (20.5) 74,545 (34.2)  < 0.001
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Table 2 The risk of  atrial fibrillation according to  the  cumulative number of  MetS and  each component diagnosed 
during four health examinations (0 to 4 times)
Model 1 is unadjusted
Model 2 is adjusted for age, sex, smoking status, alcohol intake, regular exercise, and low income
Model 3 is adjusted for age, sex, smoking status, alcohol intake, regular exercise, low income, waist circumference, systolic blood pressure, fasting glucose, logarithm 
of TG, and HDL-C level
AF atrial fibrillation, IR incidence rate, PY person-years, HR hazard ratio, CI confidence interval, HDL-C high-density lipoprotein cholesterol, TG triglycerides
The number of meeting 
the component
No. of participants AF IR (1000PY) HR (95% CI)
Model 1 Model 2 Model 3
Metabolic syndrome
 0 1,800,268 7584 0.80 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 1 428,143 3025 1.35 1.69 (1.62–1.77) 1.21 (1.16–1.27) 1.18 (1.13–1.24)
 2 250,073 2248 1.72 2.16 (2.06–2.27) 1.37 (1.31–1.44) 1.31 (1.25–1.39)
 3 188,847 2071 2.10 2.64 (2.52–2.77) 1.55 (1.48–1.63) 1.46 (1.38–1.55)
 4 217,858 3184 2.81 3.54 (3.39–3.69) 1.87 (1.80–1.95) 1.72 (1.63–1.82)
p < 0.001 p < 0.001 p < 0.001
Increased waist circumference
 0 2,063,537 10,304 0.95 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 1 298,977 2292 1.47 1.55 (1.48–1.63) 1.24 (1.19–1.30) 1.12 (1.06–1.17)
 2 171,305 1487 1.66 1.76 (1.67–1.86) 1.31 (1.24–1.39) 1.13 (1.06–1.20)
 3 147,806 1570 2.04 2.16 (2.05–2.28) 1.56 (1.48–1.64) 1.29 (1.21–1.37)
 4 203,564 2459 2.32 2.46 (2.35–2.57) 1.76 (1.69–1.84) 1.35 (1.27–1.44)
p < 0.001 p < 0.001 p < 0.001
Impaired fasting glucose
 0 1,290,283 5344 0.78 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 1 682,047 3952 1.10 1.41 (1.35–1.47) 1.11 (1.06–1.16) 1.08 (1.03–1.12)
 2 385,692 2949 1.46 1.87 (1.79–1.95) 1.22 (1.17–1.28) 1.16 (1.10–1.21)
 3 244,101 2323 1.82 2.33 (2.22–2.45) 1.30 (1.23–1.36) 1.19 (1.13–1.26)
 4 283,066 3544 2.41 3.08 (2.96–3.22) 1.39 (1.33–1.45) 1.22 (1.15–1.29)
p < 0.001 p < 0.001 p < 0.001
Low HDL‑C
 0 1,817,377 9598 1.00 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 1 439,918 2973 1.29 1.29 (1.24–1.34) 1.17 (1.12–1.22) 1.15 (1.10–1.20)
 2 242,845 1817 1.43 1.43 (1.36–1.50) 1.23 (1.17–1.29) 1.19 (1.13–1.26)
 3 182,602 1585 1.65 1.65 (1.56–1.74) 1.40 (1.32–1.47) 1.35 (1.28–1.43)
 4 202,447 2139 2.02 2.02 (1.92–2.11) 1.52 (1.45–1.59) 1.44 (1.37–1.52)
p < 0.001 p < 0.001 p < 0.001
Elevated blood pressure
 0 994,829 3048 0.58 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 1 568,202 2461 0.82 1.42 (1.34–1.49) 1.12 (1.07–1.19) 1.13 (1.07–1.19)
 2 417,544 2492 1.14 1.96 (1.86–2.07) 1.33 (1.26–1.41) 1.35 (1.28–1.43)
 3 343,192 2510 1.40 2.41 (2.29–2.54) 1.41 (1.34–1.49) 1.44 (1.36–1.53)
 4 561,422 7601 2.59 4.48 (4.29–4.67) 1.97 (1.88–2.05) 1.96 (1.87–2.07)
p < 0.001 p < 0.001 p < 0.001
Elevated TG
 0 1,284,347 6255 0.92 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
 1 506,800 3189 1.20 1.30 (1.24–1.35) 1.07 (1.02–1.11) 1.06 (1.01–1.11)
 2 352,286 2415 1.31 1.42 (1.35–1.48) 1.06 (1.01–1.12) 1.05(1.00–1.11)
 3 316,707 2435 1.46 1.59 (1.51–1.66) 1.15 (1.09–1.20) 1.13 (1.08–1.20)
 4 425,049 3818 1.71 1.86 (1.79–1.94) 1.29 (1.24–1.34) 1.27 (1.21–1.34)
p < 0.001 p < 0.001 p < 0.001
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Both MetS and AF confer a high burden of cardio-
vascular morbidity and mortality, and the association 
between MetS and AF has been reported in various stud-
ies [10, 11, 26, 27]. Compelling evidence supports that 
MetS itself is associated with the development of AF, and 
the presence of an increasing number of MetS compo-
nents predisposes individuals to a higher risk of AF [11, 
26, 28–30]. However, these studies analyzed the num-
ber of MetS components at a single point. In contrast to 
previous studies, we have investigated the influence of 
temporal accumulation of MetS by combining four serial 
health examinations collectively. While participants diag-
nosed with MetS once had an 18% increased risk of AF 
compared to that in non-MetS participants, those diag-
nosed with MetS repeatedly at four times of measure-
ment had a 72% higher risk of AF. Notably, the risk of 
AF increased by 3.1-fold as the number of fulfilled MetS 
components increased to a total of 20 counts during con-
secutive health examinations. Such a positive increase 
in AF according to a repetitive diagnosis of metabolic 
components might suggest a dose–response (or tempo-
ral accumulation) perspective in evaluating the hazards 
of cardiovascular diseases. This finding is noticeable 
because it implicates that the risk of AF development is 
different among patients with metabolic derangements 
depending on the past and upcoming metabolic burden. 
Given the proportional increase in AF risk according 
to the degree of metabolic burden integrating temporal 
changes, it is plausible to infer that the risk of AF would 
be higher in those diagnosed with MetS more than four 
times during their health examination checkups.
Regarding the relationship between elevated TG and 
the risk of AF, there were controversial reports [11, 26, 
28, 31, 32]. The Niigata Preventive Medicine Study and 
post-hoc analysis from the ARIC study reported that 
hypertriglyceridemia was not related to incident AF [11, 
26]. In addition, a recent study reported no association 
between elevated TG levels and the risk of AF [32]. How-
ever, the Multi-Ethnic Study of Atherosclerosis (MESA) 
and the Framingham Heart Study (FHS) reported that 
hypertriglyceridemia was associated with a higher risk of 
AF [31]. In our study, meeting the criteria of elevated TG 
once or twice during 4 times of health screening exami-
nations seems insignificantly or minimally associated 
with the risk of AF. Nonetheless, the association became 
evident as elevated TG levels were repeatedly checked, 
whereby the risk of AF was as high as 27% if hypertri-
glyceridemia was repeatedly confirmed through the 
entire health examinations of the study period, even after 
adjusting for potential confounders and other MetS com-
ponents. Elevated TG is reported to be associated with 
endothelial dysfunction and the presence of microvascu-
lar disease [33, 34], which could be an early manifestation 
of atherosclerosis. Moreover, it is related to an increased 
risk of recurrent coronary artery disease [35], as well as 
insulin resistance, and is known to increase blood glucose 
Fig. 2 Incidence of atrial fibrillation according to the a cumulative number of MetS diagnosed at each health examination, b cumulative number 
of each component of MetS diagnosed at each health examination, and c cumulative number of total MetS components diagnosed during four 
health examinations. WC waist circumference, HDL-C high‑density lipoprotein cholesterol, TG triglycerides
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levels [36]. Although the exact mechanism of the devel-
opment of AF is not known, the pro-atherogenic prop-
erty of elevated TG might play a role in AF development.
Along with hypertriglyceridemia, other metabolic com-
ponents and MetS itself could be linked to a higher risk of 
AF by several pathophysiological mechanisms. Mechani-
cal alterations including an increase in atrial size and 
ventricular hypertrophy due to MetS, obesity, hyperten-
sion, and low HDL-C may contribute to the development 
of AF [14, 37–40]. Atrial interstitial fibrosis, abnormal 
calcium homeostasis, and inappropriate neurohumoral 
activation led by insulin resistance are also reported to 
increased AF susceptibility [41]. Moreover, elevated levels 
of inflammation and oxidative stress have been proposed 
in the pathogenesis of both MetS and AF; indeed, HDL-C 
exerts anti-inflammatory and anti-oxidative activities 
that promote vascular health; hence, low HDL-C levels 
are related to a proinflammatory milieu [42–44]. These 
metabolic changes may predispose patients with MetS 
or individual metabolic components to AF development. 
Meanwhile, elevated BP and low HDL-C levels have the 
most prominent increase in AF risk, which is consist-
ent with prior research [11, 27]. Impaired fasting glu-
cose showed only a modest increase in AF development, 
consistent with a recent study evaluating the impact of 
‘exposure’ to metabolic syndrome on the increased risk of 
MI and stroke, both sharing common predisposing fac-
tors with AF [21]. Although the exact underlying mecha-
nisms explaining the differences in magnitudes of AF risk 
among metabolic components are not answered in the 
present study, we could hypothesize that elevated BP and 
adverse lipid profiles play more pivotal roles on substrate 
formation for AF development. Also, as the prominent 
increase in the risk of AF according to repeated checks 
of impaired fasting glucose was attenuated after adjusting 
for other covariates, it might still contribute to the devel-
opment of AF as a cluster of metabolic diseases rather 
than carry a sole dominant effect.
The International Diabetes Federation (IDF) estimates 
that approximately 25% of the world’s population, which 
Table 3 The risk of  atrial fibrillation according to  the  cumulative number of  total MetS components diagnosed 
during four health examinations (0 to 20 times)
Model 1 is unadjusted
Model 2 is adjusted for age, sex, smoking status, alcohol intake, regular exercise, and low income
Model 3 is adjusted for age, sex, smoking status, alcohol intake, regular exercise, low income, waist circumference, systolic blood pressure, fasting glucose, logarithm 
of TG, and HDL-C level
AF atrial fibrillation, IR incidence rate, PY person-years, HR hazard ratio, CI confidence interval
The number of meeting 
individual components
No. of participants AF IR (1000PY) HR (95% CI)
Model1 Model2 Model3
0 278,704 549 0.37 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
1 297,650 729 0.37 1.25 (1.12–1.39) 1.03 (0.92–1.15) 1.04 (0.93–1.16)
2 283,079 939 0.63 1.69 (1.52–1.88) 1.21 (1.09–1.34) 1.24 (1.11–1.38)
3 265,009 1007 0.72 1.94 (1.75–2.15) 1.23 (1.11–1.36) 1.27 (1.14–1.41)
4 263,875 1345 0.97 2.61 (2.36–2.88) 1.43 (1.30–1.58) 1.49 (1.35–1.65)
5 235,071 1342 1.08 2.92 (2.65–3.23) 1.47 (1.33–1.62) 1.54 (1.39–1.71)
6 210,455 1397 1.26 3.41 (3.09–3.76) 1.59 (1.44–1.75) 1.68 (1.52–1.87)
7 187,332 1427 1.45 3.92 (3.55–4.32) 1.72 (1.56–1.90) 1.84 (1.66–2.04)
8 173,024 1407 1.55 4.18 (3.79–4.62) 1.74 (1.58–1.93) 1.87 (1.68–2.08)
9 144,294 1282 1.70 4.58 (4.15–5.06) 1.85 (1.67–2.05) 2.00 (1.79–2.23)
10 122,156 1179 1.85 4.99 (4.50–5.52) 1.94 (1.75–2.15) 2.10 (1.88–2.34)
11 100,785 1046 1.99 5.37 (4.84–5.96) 2.03 (1.82–2.25) 2.20 (1.96–2.46)
12 89,005 980 2.11 5.70 (5.13–6.33) 2.07 (1.86–2.30) 2.24 (2.00–2.51)
13 68,103 855 2.41 6.51 (5.85–7.25) 2.29 (2.06–2.56) 2.49 (2.21–2.80)
14 52,236 723 2.66 7.19 (6.43–8.03) 2.46 (2.19–2.75) 2.66 (2.35–3.00)
15 38,764 572 2.84 7.67 (6.82–8.62) 2.57 (2.29–2.90) 2.78 (2.44–3.16)
16 32,590 556 3.29 8.88 (7.89–9.99) 2.81 (2.50–3.17) 3.04 (2.66–3.46)
17 17,981 316 3.39 9.16 (7.98–10.52) 2.87 (2.50–3.30) 3.03 (2.61–3.52)
18 11,711 204 3.36 9.07 (7.73–10.66) 2.81 (2.39–3.30) 2.93 (2.46–3.48)
19 7451 136 3.52 9.50 (7.87–11.46) 2.94 (2.43–3.55) 3.03 (2.48–3.69)
20 5914 121 3.97 10.73 (8.81–13.06) 3.15 (2.58–3.84) 3.11 (2.52–3.83)
p < 0.001 p < 0.001 p < 0.001
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corresponds to over a billion people, is affected by MetS 
despite the fact that the prevalence varies widely accord-
ing to age, ethnicity, and sex of the population studied 
[45, 46]. Considering that AF is strongly associated with 
cardiovascular diseases such as stroke, heart failure, myo-
cardial infarction, dementia, and increased mortality [3, 
47], exploring the pragmatic association between meta-
bolic derangements and AF along with the understanding 
of potential subsequent diseases is important to address 
the public health care burden of AF and AF-related com-
plications. Our large study population with a mean age at 
mid-forties, much younger than that reported in previous 
studies [11, 26, 27], thereby representing the most active 
group socioeconomically, contributes to emphasize the 
awareness of the group harboring the risk of AF and the 
early initiation of prevention strategies. Importantly, we 
ascertained that even meeting one or two components 
of MetS over time is sufficient to increase the risk of AF, 
and thus, it would be crucial to make a concerted effort 
to minimize the metabolic derangements.
Even within the participants who presented the same 
cumulative number of total MetS components in the 
four health examinations, each may carry a different risk 
of AF depending on the change in metabolic burden. 
Those with a decreased number of MetS components 
over time showed a lower risk of AF than participants 
with an increase or maintenance in the number of MetS 
components at the last health examination compared to 
the first examination. Given that recovery from MetS is 
known to be significantly associated with a decreased risk 
of major adverse cardiovascular events [48], our results 
are consistent with previous findings by focusing on the 
Fig. 3 Kaplan‒Meier estimates of cumulative incidence probability of AF according to the cumulative number of a MetS, b increased waist 
circumference, c impaired fasting glucose, d low HDL‑C, e elevated blood pressure, and f elevated TG during four health examinations. AF atrial 
fibrillation, MetS metabolic syndrome, WC waist circumference, HDL-C high‑density lipoprotein cholesterol, BP blood pressure, TG triglycerides
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most common cardiac rhythm disorder, AF. Therefore, 
it would be important to manage MetS component(s) to 
mitigate the risk of AF, and this management should be 
considered as part of the overall management strategy 
for preventing AF [49, 50]. Indeed, lifestyle modification 
(including addressing many risk factors within the MetS 
components) is part of the atrial fibrillation better care 
(ABC) pathway for holistic AF care, which is advocated 
in the new 2020 ESC guidelines [51].
Limitations
Our study has several limitations. First, a considerable 
proportion of the study population already had diabetes 
mellitus and hypertension, which are evident and strong 
risk factors for AF. Instead, we show the risk gradient of 
AF by investigating the cumulative burden of metabolic 
derangements in a large general population at a relatively 
young age. Second, more than two-thirds of the study 
participants were men because employees are more likely 
to undergo regular health examinations provided at work 
places; hence, selection bias of sex might be introduced. 
However, subgroup analysis did not show any significant 
interaction with sex. Third, the degree and the relation-
ship of AF risk with metabolic burden may differ in west-
ern populations because our study was conducted in an 
Asian population. Fourth, we incorporated many covari-
ates including lifestyle behaviors, but unavailable con-
founding and unmeasured factors such as the presence of 
other inflammatory diseases or the measure of left atrial 
size could not be fully adjusted. Fifth, the metabolic sta-
tus may change during the follow-up period and mitigate 
the risk. Lastly, the causality and underlying mechanistic 
link between MetS and AF were not answered. Never-
theless, we expanded the previous understanding of the 
Fig. 4 The risk of atrial fibrillation according to the temporal trends in metabolic burden. No number, MetS metabolic syndrome
Page 11 of 13Ahn et al. Cardiovasc Diabetol           (2021) 20:20  
association between MetS and AF by showing the bio-
logical gradient of metabolic derangements and AF risk 
in this large population-based study with serial health 
examination data.
Conclusions
In this large Asian population-based cohort, the cumu-
lative burden of MetS diagnostic criteria and its compo-
nents  over time has a positive correlation with the risk 
of incident AF. Given the close association between the 
cumulative number of total MetS components and the 
risk of AF, maximal effort to detect and correct metabolic 
derangements even before the development of MetS 
might be important to prevent AF and related cardiovas-
cular diseases.
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